Overview

Modified Conditioning Regimen for CML-BP

Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-14
Target enrollment:
Participant gender:
Summary
Study on the Efficacy and Safety of a Reduced-Toxicity Conditioning Regimen Containing Thiotepa and Melphalan in Patients with Blast Phase Chronic Myeloid Leukemia
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Treatments:
Melphalan